ICAAC In Brief: Gilead's adefovir dipivoxil
Executive Summary
Gilead's adefovir dipivoxil: Phase I/II trial results in 15 patients show adefovir 125 mg once daily for 28 days decreases hepatitis B viral load by 97% or 1.8 log compared to a 7% increase in viral load in patients receiving placebo. Patients' viral levels returned to baseline one to six weeks after discontinuing adefovir therapy. Side effects with adefovir included nausea and transient hepatic transaminase elevations. Adefovir (GS 840) is in Phase II/III studies for combination treatment of HIV infection...